Accumulating evidence suggested that patients with PIK3CA-mutated ESCC might benefit from treatment with PI3K inhibitors, like PI3K inhibitor CYH33, which could play potent therapeutic activity against ESCC and could be used as a sensitizer during radiotherapy.[22,23]. Here, PIK3CA is linked to esophageal squamous cell carcinoma.